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Multifunctional, lipopolyplex formulations comprising a mixture of cationic liposomes and cationic,
receptor-targeting peptides have potential use in gene therapy applications. Lipopolyplex formulations
described here are typically far more efficient transfection agents than binary lipoplex or polyplex
formulations. It has been shown previously that the peptide component mediates both DNA packaging and
targeting of the nanoparticle while in this report we investigate the contribution of the lipid component.We
hypothesised that the lipid components synergise with the peptides in the transfection process by promoting
endosomal escape after lipid bilayer fusion. Lipopolyplexes were prepared with cationic liposomes
comprising DOTAP with either neutral lipid DOPE or DOPC. DOPE promotes fusogenic, inverted
hexagonal lipid structures while DOPC promotes more stable laminar structures. Lipopolyplexes
containing DOPE showed substantially higher transfection efficiency than those formulated with DOPC,
both in vitro and in vivo. DOPE-containing lipopolyplexes showed rapid endosomal trafficking and nuclear
accumulation of DNA while DOPC-containing formulations remained within the late endo-lysosomal
compartments. These findings are consistent with previous finding for the role of DOPE in lipoplexes and
support the hypothesis regarding the function of the lipid components in lipopolyplexes. These findings will
help to inform future lipopolyplex design, strategies and clinical development processes.
S
ynthetic, non-viral vectors offer advantages over viral vectors for in vivo gene therapy in that they are less
immunogenic, have fewer packaging constraints and are safer1,2. Cationic lipoplexes and polyplexes pre-
dominate in the non-viral vector field but increasingly lipopolyplex formulations, which are combinations
of lipids with peptides or polymers, are being explored as appreciation develops of their wider range of function-
alities and higher transfection efficiencies3–11. Further detailed functional and structural studies are required to
understand the properties of lipopolyplexes, how to formulate components and to develop improved
formulations.
We are developing a lipopolyplex formulation termed a Receptor Targeted Nanocomplex (RTN), which is a
mixture of cationic, receptor-targeting peptides and cationic liposomes with plasmidDNA (pDNA)12–17. The lipid
and peptide components of RTNs feature modular design elements that enable their functionality to be dissected
at the molecular level13. We have shown previously that the peptide mediates DNA packaging and receptor
targeting and so the focus of this study was to investigate the function of the lipids and how they contribute to the
transfection efficiency of RTN lipopolyplexes. Endosomolysis is a major obstacle to transfection with peptide-
DNA formulations and so we hypothesised that addition of the liposome to the peptide might enhance transfec-
tion by promoting fusion with the endosomal membrane, leading to improved cytoplasmic release of the
DNA13,18. The neutral lipid DOPE in cationic lipoplex formulations enables higher transfection efficiencies as
the conical structure of this lipid promotes the formation of inverted hexagonal structures that rapidly fuse with
the endosomal lipid bilayer, independent of charge, thus enabling cytoplasmic release of the DNA. Substitution of
DOPE for DOPC, a neutral lipid that favour more stable lamellar structures, greatly reduces lipoplex transfection
efficiency18–22.
In this study, we aimed to explore whether the lipid components of the RTN lipopolyplex played a similar role
in endosomal membrane fusion to that of lipoplexes and whether this contributed to their improved transfection
efficiency. RTN formulations were therefore formulated with peptides mixed with cationic liposomes at the same
charge density, containing either the fusogenic neutral lipidDOPE, or the non-fusogenic, neutral lipidDOPC.We
hypothesised that if charge density of the liposome component was the more important factor then substituting
the neutral lipid component would not affect transfection efficiency whereas if fusogenic properties were more
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important, the DOPE formulations would be superior to the DOPC
formulations. The biophysical properties, transfection efficiencies
and intracellular trafficking properties of each were investigated
and compared to relate structural differences to functionality.
Finally, in vivo transfection efficiencies of RTNs containing DOPE
or DOPCwere compared to assess the relevance of in vitro studies to
in vivo applications.
This study will enable us to understand in more detail how such
formulations function and to develop them further for gene therapy
applications.
Methods
The lipids (Supplementary Fig. 1) 1,2-dioleoyl-3-trimethylammonium-propane
(DOTAP), 1,2-dioleoyl-sn-glycero-sn-3-phosphatidylcholine (DOPC), 1,2-dioleoyl-
sn-glycero-3-phosphatidyl-ethanolamine (DOPE) and Rhodamine-DOPE were
purchased from Avanti Polar Lipids (Birmingham, Alabama, USA). The peptide
sequences K16GACSERSMNFCG (K16E) and K16GACYGLPHKFCG (K16Y) were
purchased from China Peptides (Shanghai, China) and dissolved to 10 mg/mL in
DNase/RNase free water (Invitrogen, Paisley, UK). The plasmid pCI-Luc comprised
the luciferase gene of pGL3 (Invitrogen, Paisley, UK) subcloned into the eukaryotic
expression vector pCI (Promega, Southampton, UK).
Liposome, lipoplex and lipopolyplex formulation. The liposomes LC1, LC2 and LC3
comprised formulations of DOTAP: and DOPC weight ratios of 0.551, 151 and 351
respectively (DOTAP5DOPC). The homologous DOTAP/DOPE liposomes LE1, LE2
and LE3 comprised a mixture of DOTAP and DOPE at weigh ratios of 0.551, 151 and
351 respectively. Liposomes were prepared bymixing the component lipids dissolved
in chloroform to a final volume of 200 mL, followed by rotary evaporation in a Buchi
Rotavapor (Oldham, UK) under a partial vacuum to produce a thin lipid film. Lipids
were then rehydrated with 1 ml of distilled water whilst rotating overnight and then
sonicated in a XB3 Ultrasonic Bath (Grant Instruments, Cambridge, UK) until clear
to make the liposome solution at 1 mg/ml.
Lipoplexes (LD) were then formed bymixing the cationic liposomes with pDNA at
a weight ratio of 451 lipid (L)5DNA (D), in distilled water or OptiMEM (Invitrogen,
Paisley, UK) with DNA at a final concentration of 1 mg per 100 ml. LDmixtures were
then incubated for 30 min at room temperature to stabilise before use. Lipid
(L)5Peptide (P)5DNA (D) formulations were prepared by mixing the different
liposomes with peptide in the order L5P5D at weight ratios of 0.55451, 0.755451,
15451 and 25451.
Hydrodynamic size and zeta potential measurements. The hydrodynamic size and
zeta potential of the liposomes (5 mg lipid perml), LD and LPD nanocomplexes (both
at 2 mg/ml with respect to plasmid DNA) in distilled water were determined by
dynamic light scattering (DLS) and laser Doppler velocimetry, respectively, using a
Malvern Nano ZS (Malvern Instruments, Malvern, UK). The z-average data are
reported with Polydispersity Index (PDI) values of less than 0.3 accepted as
representing a monodisperse population of particles. The overall charge (zeta
potential) that the nanocomplex acquires in water while attracted by the oppositely
charged electrode was measured and reported as strength field unit (mV).
Negative staining transmission electron microscopy (TEM). A 5 ml aliquot of LPD
nanocomplexes was applied onto a 300-mesh copper grid coated with a Formvar/
carbon support film (Agar Scientific, Essex, UK) then, after a few seconds, dried by
blotting with filter paper. The sample was then negatively stained with 1% uranyl
acetate for a few seconds, before blotting with filter paper and air dried. Imaging was
carried out with a Philips CM120 BioTwin Transmission Electron Microscope and
operated at an accelerating voltage of 120 kV.
Cell culture and luciferase transfection. The human bronchial epithelial cell line
16HBE14o- (D. Gruenert, San Francisco) was maintained in Eagle’s Minimal
Essential Medium (MEM; Sigma-Aldrich, Dorset, UK) supplemented with 10% (v/v)
foetal bovine serum (FBS), 100 U/mL penicillin, 100 mg/mL streptomycin, and
2 mmol/l L-glutamine. The murine neuroblastoma cell line Neuro-2A (ATCC,
Manassas, VA, USA) was cultured in Dulbecco’s Modified Eagle Medium (DMEM),
1% (v/v) non-essential amino acids, 1 mM sodium pyruvate and 10% (v/v) FBS
(Invitrogen, Paisley, UK). Both cell lines were incubated at 37uC in a humidified
atmosphere with 5% CO2. For transfections, cells were seeded into 96-well plates at
2.5 3 104 cells per well then LD or LPD nanocomplexes in OptiMEM added to each
well containing 250 ng of plasmid DNA in 200 ml in replicates of six. Plates were
centrifuged at 4833 g for 5 min to promote sedimentation of the nanocomplexes and
incubated for a further 24 h. Cells were then lysed with Reporter Lysis Buffer and a
chemiluminescence assay was performed to measure luciferase activity (Promega,
Southampton, UK). Protein concentration in the lysate was determined using a Bio-
Rad protein assay (Hemel Hempstead, UK) then luciferase activity expressed as
relative light units (RLU) per milligram of protein.
Confocal microscopy. Fluorescently-labelled LPD formulations were prepared with
LC2 or LE2 liposomes containing Rhodamine-DOPE at 0.5% of total lipid while 50% of
the pCI-Luc was labelled with Cy5 dye using the Universal Linkage System Nucleic
Acid Labelling Kit (Kreatech Diagnostics, Amsterdam, Netherlands). 15 3 104
16HBE14o- cells were seeded onto glass coverslips in 6-well plates and incubated for
24 h at 37uC in a humidified atmosphere with 5% CO2. Fluorescently-labelled
nanocomplexes LC2PD-0.75 and LE2PD-0.75 (Table 1) were added to the cells (1.5 mg
DNA/well), the plates were centrifuged at 483 3 g for 5 min and then incubated for
6 h or 22 h. The cells were then fixed with 4% paraformaldehyde, permeabilised with
0.1% Triton in phosphate-buffered saline, blocked with 3% bovine serum albumin
(BSA), and stained for 2 h at room temperature with anti-Lysosomal-associated
membrane protein 1 (LAMP-1) primary antibody (15250 dilution in 1% BSA;
product number H4A3, Abcam, Cambridge, UK), washed with phosphate-buffered
saline and then incubated for 1 h at room temperature with Alexafluor 488 goat anti-
mouse secondary antibody (151000 dilution in 1% BSA, Invitrogen, Paisley, UK) and
DAPI (0.1 mgmL21, Sigma-Aldrich, Poole, UK). The cells were washed and sealed in
mounting media (Invitrogen, Paisley, UK) before visualising with a 63 3 oil
immersion objective (N.A. 1.4) under a Carl Zeiss LSM710 laser scanningmicroscope
system (Carl Zeiss, Jena, Germany).
In vivo delivery and luciferase assay on lung tissues. Female CD1 mice were
purchased from Charles River (Margate, UK). All procedures were approved by UCL
animal care policies and were carried out under Home Office Licenses issued in
accordance with the United Kingdom Animals (Scientific Procedures) Act 1986
(UK). LC1PD and LE1PD complexes were prepared at a weight ratio of L5P5D of
0.755451 essentially as described previously15 at a final pDNA concentration of
0.33 mg/ml. 4-week old female CD1 mice were instilled oropharyngeally with
nanocomplexes in 55 ml water containing 18.15 mg of pCI-Luc, with untreated mice
used as controls (n 5 3). 24 h following instillation, the mice were culled and their
lungs extracted and snap frozen. Lungs were defrosted on ice, submerged in reporter
gene assay lysis buffer (Roche, Basel, Switzerland), homogenized with a Precellys24
tissue homogenizer (Stretton Scientific, Stretton, Derbyshire, UK) and then
centrifuged at 14,170 3 g for 10 min at 4uC. The supernatant was removed and
centrifuged for a further 10 min at 4uC then used in luciferase assays. Results were
expressed as relative luminescence units per milligram of protein (RLU/mg).
Statistical analysis. Data are shown as mean 6 standard deviation (S.D.). Statistical
analysis was performed by unpaired t-test using GraphPad Prism Statistics software
version 5.01 (GraphPad Software, Inc, La Jolla, CA, USA). A difference was
considered statistically significant when P , 0.05.
Results
The morphology of the representative samples. Biophysical analysis
by transmission electron microscopy (TEM) (Fig. 1) and dynamic
light scattering analysis (Table 1) showed that LC1PD-0.75 for-
mulations formed spherical particles of 78 6 0.6 nm (PDI , 0.3)
and a zeta potential of 36.66 1.8 mVwith a tendency to agglomerate
(Fig. 1A). LE1PD-0.75 formulations, in which DOPE replaced DOPC,
formed mostly spheres (Fig. 1B) of a similar size 85.5 6 0.6 nm (PDI
, 0.3) but much higher zeta potential at162.5 mV than LC1PD-0.75.
On the other hand, LC3PD-0.75 and LE3PD-0.75 both formed mostly
spheres of both similar size about 74 nm (PDIs , 0.3) and zeta
potential at 142 and 139 mV respectively. Both also formed some
rod-like structures in addition to sphere at about 10 nm wide and
40 nm long (Fig. 1C, D). Increasing the DOTAP content in the
formulations LC1PD-0.75 (78 nm) to LC2PD-0.75 (68 nm) to
LC3PD-0.75 (74 nm) produced no pattern in size changes but for
the homologous DOPE formulations size decreased from 86 nm to
74 nm.
Luciferase transfection of LD and LPD nanocomplexes. The tran-
sfection efficiency of LC1-3D complexes (451 L5D weight ratios)
improved with decreasing WDOPC in both 16HBE14o- and Neuro-2A
cells (Supplementary Fig. 1), while there was no consistent trend when
varying WDOPE for the transfection efficiency of LE1-3D lipoplexes. This
pattern of results was consistent with previously reported transfection
data with DOPC and DOPE-containing lipoplexes19,20.
The transfection efficiency of LEPD was significantly higher than
that of LCPD nanocomplexes at the same weight ratio of liposome to
pDNA (Fig. 2A–C). The transfection efficiencies of LCPD lipopoly-
plexes increased with decreasingWDOPC (Fig. 2D) while there was no
consistent trend seen with decreasing WDOPE (Fig. 2E).
Confocal microscopy. Cy-5-labelled pDNA (green) and Rhodamine-
labelled liposome (red) were used to monitor the trafficking of
LPD inside 16HBE14o- cells. Subcellular localisation of the vector
components was assessed in relation to the late endosomal-lysosomal
www.nature.com/scientificreports
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compartment marker (LAMP-1, magenta) and DAPI- stained nuclei
(blue). At 6h, LC2PD-0.75 accumulated in perinuclear lysosomes (yellow
dots representing colocalised Cy5-DNA and rhodamine-lipids)
(Fig. 3A) and even after 22 h, most pDNA still resided in the late
endosomes/lysosomes with very little free pDNA found in the
cytoplasm or the nucleus (Fig. 3B). In contrast, free pDNA from
LE2PD-0.75 complexes was found in the cytoplasm and nucleus as
early as 6 h (Fig. 3C) which further increased by 22 h (Fig. 3D).
Luciferase assay of lung extracts. Finally we determined whether the
in vitro results translated to an in vivo application by delivery to the
airways of murine lungs. Twenty-four hours after administration,
luciferase assays were performed on lung extracts of mice treated
with either LC1PD-0.75 or LE1PD-0.75 nanocomplexes. These
formulations were selected as they exemplified the effects of the
neutral lipids on transfection efficiency in vitro. The luciferase
expression from LE1PD-0.75 was five-fold higher than LC1PD-0.75
(Fig. 4) while the same formulations transfecting 16HBE14o- cells
confirmed that LE1PD-0.75 was again significantly better than the
LC1PD-0.75 nanocomplexes (Supplementary Figure 2).
Discussion
We are developing formulations of lipids with peptides and DNA
which self-assemble into nanoparticles electrostatically on mixing at
optimised ratios of components13–17. The transfection efficiency of
these lipopolyplexes is substantially higher than either the lipoplex or
polyplex containing the same liposomes or peptides and so we aim to
clarify the mechanism of synergy of the lipid and peptide compo-
nents. We hypothesised that, while the peptide mediates packaging
and targeting15,16,21 lipid components of lipopolyplexes may aid in
endosomal disruption and the trafficking of the nucleic acid into the
cytoplasm and therefore reasoned that strongly fusogenic lipids, such
as DOPE, should display higher transfection efficiencies in lipopo-
lyplexes than DOPC that promotes more stable laminar lipid bilayer
structures.
Biophysical analysis revealed that lipopolyplex formulations con-
taining DOPE and DOPC lipids in variable proportions, were of a
consistent size and charge with only marginal affects of alterations to
the lipid composition of each formulation. TEM images showed that
there were no significant differences in lipopolyplex morphology
with a mixture of spheres and rods observed in most cases of similar
sizes. Despite onlyminor differences in biophysical properties, trans-
fection results of LCPD and LEPD lipopolyplexes revealed that at
higher weight fractions of neutral lipids (i.e., those containing LE1
and LC1) the transfection efficiency of LEPD formulations was sig-
nificantly higher than that of LCPDs. As theweight fraction of neutral
lipids decreased and the liposome charge density increased, the rela-
tive transfection efficiency of LCPDs was enhanced although even
with lipids at the highest charge density, i.e., LE3 and LC3, the trans-
fection efficiency of LEPD formulations remained approximately
twice that of LCPD formulations. These same trends were also
observed with LED and LCD lipoplex transfections, with LCD trans-
fection efficiencies increasing significantly with higher charge den-
sity while the LED formulations showed no consistent trend in
relation to charge density. The transfection enhancement of LD
and LPD complexes containing DOPE rather than DOPC indicates
the importance of the inverted hexagonal structure of theDOPE lipid
in enabling endosomal membrane fusion and release of DNA com-
pared to the lamellar DOPC structure. Cellular trafficking studies
confirmed that the DOPC-containing cationic liposomes showed
limited ability to escape from the endosome leading to lower trans-
fection efficiencies of lipopolyplexes.
Finally, we investigated whether DOPE can improve the trans-
fection efficiency of the RTN lipopolyplex in vivo by delivery to
murine lungs (Fig. 4). LE1PD-0.75 yielded luciferase reporter
gene expression levels five times higher than that of LC1PD-0.75
Figure 1 | Transmission electron microscopy of LPD nanocomplexes.
(A) Images of LC1PD-0.75, (B) LE1PD-0.75, (C) LC3PD-0.75 and
(D) LE3PD-0.75 nanocomplexes. Positively-stained spherical particles and
negatively stained rods are evident in all images. Scale bar is 500 nm for all
images.
Table 1 | Hydrodynamic size and zeta potential of LPD nanocom-
plexes formed at different weight ratios LC15P5D and LE15P5D as
measured by dynamic light scattering (n 5 3, mean 6 standard
deviation)
Formulation
(LPD)
L5P5D
(weight%) Size (nm) PDI Zeta (mV)
LC1PD-0.5 0.55451 65.9 6 1.1 0.145 33.8 6 0.4
LC1PD-0.75 0.755451 77.9 6 0.6 0.144 36.6 6 1.8
LC1PD-1 15451 68.7 6 0.5 0.153 40.6 6 2.8
LC1PD-2 25451 76.1 6 0.1 0.247 60.7 6 2.7
LE1PD-0.5 0.55451 79.4 6 0.3 0.245 68.8 6 11.2
LE1PD-0.75 0.755451 85.5 6 0.6 0.299 62.5 6 1.0
LE1PD-1 15451 100.6 6 0.9 0.333 64.6 6 2.0
LE1PD-2 25451 120.5 6 0.8 0.445 65.1 6 0.7
LC2PD-0.5 0.55451 84.8 6 0.4 0.202 44.4 6 0.4
LC2PD-0.75 0.755451 68.4 6 0.5 0.196 56.5 6 0.5
LC2PD-1 15451 85.2 6 1.4 0.155 51.3 6 1.4
LC2PD-2 25451 118.3 6 1.1 0.237 45.5 6 1.2
LE2PD-0.5 0.55451 65.7 6 0.4 0.240 58.9 6 1.5
LE2PD-0.75 0.755451 92.1 6 1.3 0.371 57.7 6 2.7
LE2PD-1 15451 83.7 6 0.3 0.315 63.3 6 1.2
LE2PD-2 25451 94.6 6 2.0 0.442 67.7 6 1.2
LC3PD-0.5 0.55451 76.1 6 1.9 0.288 40.5 6 1.5
LC3PD-0.75 0.755451 74.5 6 0.7 0.158 41.8 6 1.7
LC3PD-1 15451 67.6 6 0.3 0.250 46.8 6 4.7
LC3PD-2 25451 99.6 6 1.7 0.350 56.0 6 1.6
LE3PD-0.5 0.55451 78.0 6 0.6 0.263 53.4 6 8.1
LE3PD-0.75 0.755451 73.5 6 0.9 0.218 38.5 6 2.5
LE3PD-1 15451 70.1 6 1.0 0.194 41.3 6 2.2
LE3PD-2 25451 70.4 6 0.5 0.195 48.5 6 1.9
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formulations. Thus we have shown that the advantages of DOPE
for in vitro transfections in lipopolyplexes translated to an in vivo
system. This result contrasted with a previous comparative study
of DOPE-containing lipopolyplexes where the formulation was
administered systemically and poor transfection efficiency was
observed. However, this difference was due to serum interactions
with lipopolyplexes neutralising DOPE activity before actually
entering cells22.
We have shown that the fusogenic properties of DOPE, as in
lipoplex formulations, are essential for the transfection function of
lipopolyplex formulations but we have shown additionally that this
property can be combined with the targeting and packaging prop-
erties of the peptide component to produce a significant enhance-
ment of transfection efficiency compared to the lipoplex alone.
The cationic lipid is important for the stability of the liposome
component and its electrostatic association with DNA in for-
mulating the lipopolyplex but probably does not contribute to
membrane interactions in the cellular transfection pathway.
These findings will be important in designing improved lipopoly-
plex formulations.
Figure 2 | Transfection efficiencies in 16HBE14o- cells of lipopolyplexes formulated with the targeting peptide K16GACSERSMNFCG, plasmid
pCl-Luc and liposomes with DOPE or DOPC at different weight fractions. LPD lipopolyplexes were formulated at weight ratios of liposomes5DNA of
0.5, 0.75, 1 or 2, as shown in labels. Lipopolyplexes were compared containing lipids LC1 and LE1 (A), LC2 and LE2 (B), LC3 and LE3 (C), LC1-3 (D) and LE1-3
(E). Transfection efficiency wasmeasured by luciferase activity and expressed as relative light units permg of protein (RLU/mg). Values are themeans of 6
replicates 6 standard deviation. Four stars represent p , 0.0001 and three stars represent p , 0.001.
www.nature.com/scientificreports
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